Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Ropivacaine Bolus for Shoulder Surgery
NCT02946268Phase 4Withdrawn
- Sponsor
- Duke University
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of ropivacaine in postoperative pain (3 arms), sponsored by Duke University. Primary endpoint: Optimal Volume of Ropivacaine 0.2% bolus via interscalene catheter at 1 day. Planned start Feb 2017; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02946268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946268.